She’s giving obesity medications another shot. Diane Schram, 64, lost 25 pounds with Ozempic and tirzepatide, a similar medication. After plateauing on those two drugs, Schram is trying a new experimental drug that’s being hailed as better than Ozempic .
Eli Lilly’s retatrutide, which is in clinical trials, may help users shed up to 24% of their body weight after 48 weeks. Schram is taking it at Renew Body Contouring and MedSpa in Houston as part of a clinical research study, the Fox affiliate in Houston reports . “The new retatrutide has an ability to help you retain muscle and now you’re having less side effects,” Renew owner Katina Kearns told Fox 26 on Tuesday .
Semaglutide — the active ingredient in Ozempic and Wegovy — mimics GLP-1, a hormone the body naturally produces after eating. Tirzepatide — the active ingredient in Mounjaro and Zepbound — mimics GLP-1 and GIP, another appetite-suppressing hormone. Retatrutide has earned the nickname “triple G” because it mimics GLP-1, GIP and glucagon, a hormone that helps control blood sugar levels.
Retatrutide “has a strong effect on visceral fat and liver obesity and other really difficult-to-treat types of obesity. As a result, you lose even more weight than tirzepatide,” Dave Ricks, chair and CEO of Lilly, told the Wall Street Journal last month. The outlet reported that retatrutide is in Phase 3 trials and won’t be up for approval by the Food and Drug Administration for a few years.
In the mean.
